| Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells M Daher, R Basar, E Gokdemir, N Baran, N Uprety, AK Nunez Cortes, ... Blood, The Journal of the American Society of Hematology 137 (5), 624-636, 2021 | 191 | 2021 |
| Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated blood and cord blood–derived NK cells facilitates CAR-like responses against CD30+ malignancies LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, ... Clinical Cancer Research 27 (13), 3744-3756, 2021 | 99 | 2021 |
| Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European … L Yeates, MA Slatter, S Bonanomi, FLWI Lim, SY Ong, A Dalissier, ... Bone marrow transplantation 52 (5), 762-764, 2017 | 50 | 2017 |
| Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM-2 WS Kim, TM Kim, SG Cho, I Jarque, E Iskierka-Jażdżewska, ML Poon, ... Blood 140 (Supplement 1), 1070-1071, 2022 | 27 | 2022 |
| Respiratory virus infection after allogeneic hematopoietic stem cell transplant in a tropical center: predictive value of the immunodeficiency scoring index L Wang, J Allen, C Diong, YT Goh, S Gopalakrishnan, A Ho, W Hwang, ... Transplant Infectious Disease 19 (3), e12693, 2017 | 24 | 2017 |
| The TGF-β/SMAD signaling pathway as a mediator of NK cell dysfunction and immune evasion in myelodysplastic syndrome M Daher, R Basar, H Shaim, E Gokdemir, N Uprety, A Kontoyiannis, ... Blood 130, 53, 2017 | 21 | 2017 |
| Cutaneous follicular hyperkeratotic spicules–the first clinical sign of multiple myeloma progression or relapse. LK Tay, FL Lim, HJ Ng, HY Lee, SM Pang, T Thirumoorthy International journal of dermatology 49 (8), 2010 | 21 | 2010 |
| Metabolic reprogramming of GMP grade cord tissue derived mesenchymal stem cells enhances their suppressive potential in GVHD M Mendt, M Daher, R Basar, M Shanley, B Kumar, FL Wei Inng, S Acharya, ... Frontiers in immunology 12, 631353, 2021 | 18 | 2021 |
| Cord blood NK cells engineered to express a humanized CD123-targeted chimeric antigen receptor (CAR) and IL-15 as off-the-shelf therapy for acute myeloid leukemia LN Kerbauy, S Ang, E Liu, PP Banerjee, Y Wu, H Shaim, FLWI Lim, ... Blood 130 (Supplement 1), 4453-4453, 2017 | 17 | 2017 |
| Donor‐type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant J Quek, JJ Lee, FL Lim, C Diong, YT Goh, S Gopalakrishnan, A Ho, ... Transfusion 59 (1), 335-339, 2019 | 14 | 2019 |
| Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed/refractory (R/R) diffuse large B-Cell lymphoma (DLBCL) S Ayyappan, WS Kim, TM Kim, J Walewski, SG Cho, I Jarque, ... Blood 142, 436, 2023 | 13 | 2023 |
| Artificial cell membrane polymersome-based intranasal beta spike formulation as a second generation COVID-19 vaccine JH Lam, D Shivhare, TW Chia, SL Chew, G Sinsinbar, TY Aw, S Wong, ... ACS nano 16 (10), 16757-16775, 2022 | 13 | 2022 |
| Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore’s private insurance … XJ Wang, YH Wang, SCT Li, C Gkitzia, ST Lim, LP Koh, FLWI Lim, ... Journal of Medical Economics 24 (1), 637-653, 2021 | 12 | 2021 |
| A phase 2 study of odronextamab (REGN1979), a CD20 x CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma TM Kim, A Alonso, M Prince, M Taszner, SG Cho, DA Stevens, M Poon, ... Blood 136, 28-29, 2020 | 12 | 2020 |
| Favorable outcomes of COVID‐19 in vaccinated hematopoietic stem cell transplant recipients: a single‐center experience JY Tan, LE Wee, YH Tan, EP Conceicao, FWI Lim, Y Chen, H Than, ... Transplant Infectious Disease 25 (3), e14024, 2023 | 9 | 2023 |
| Emerging CAR landscape for cancer immunotherapy FLWI Lim, SO Ang Biochemical Pharmacology 178, 114051, 2020 | 6 | 2020 |
| CAR T cell therapy in hematological malignancies: implications of the tumor microenvironment and biomarkers on efficacy and toxicity JY Tan, MH Low, Y Chen, FLWI Lim International Journal of Molecular Sciences 23 (13), 6931, 2022 | 5 | 2022 |
| Activated B cells suppress T-cell function through metabolic competition N Imahashi, R Basar, Y Huang, F Wang, N Baran, PP Banerjee, J Lu, ... Journal for immunotherapy of cancer 10 (12), 2022 | 5 | 2022 |
| An exploration of the applicability of the refined disease risk index and its integration with other independent risk factors for individualized prognostication VV Maka, LP Koh, C Diong, YT Goh, S Gopalakrishnan, A Ho, W Hwang, ... Bone Marrow Transplantation 52 (3), 363-371, 2017 | 5 | 2017 |
| Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations JY Chan, N Somasundaram, N Grigoropoulos, F Lim, ML Poon, ... Discover Oncology 14 (1), 132, 2023 | 4 | 2023 |
